PETS

• Core Strategic Priorities

  • Management remains focused on enhancing long-term shareholder value, streamlining cost structures, optimizing capital allocation, and returning the company to sustainable profitability.
  • The board of directors is evaluating all strategic and capital allocation options with strict discipline, and remains open to any opportunities that could increase shareholder value.
  • The company is diversifying its customer acquisition funnel away from increasingly expensive traditional advertising channels to improve efficiency.

• Technology and Operational Improvements

  • Completed the enterprise-wide rollout of SAP as its new ERP system in Q1 2027, marking the completion of a major element of the company's multi-quarter legacy technology transformation initiative, strengthening financial reporting and operational systems.
  • Launched a new call center platform in June 2026 that improves efficiency for handling customer inquiries and sales.
  • A new fraud prevention system launched in Q4 2026 continues to effectively protect the business as order volumes change.
  • A new freight agreement was secured that mitigates proposed carrier cost increases and delivers faster delivery (up to 2 days faster for West Coast customers), which management expects to improve customer satisfaction and retention.

• Customer and Marketing Performance

  • Net sales stabilized sequentially at above $40 million for the third consecutive quarter, though year-over-year sales declined due to ongoing softness in prescription medication sales.
  • Acquired 70,000 new customers in Q1, with new customer acquisition trending upward over multiple quarters. Reduced customer acquisition cost by 15% YoY to $60 per new customer, driven by elimination of unproductive high-cost ad programs and marketing optimization.
  • Recurring revenue share of total gross sales increased 390 basis points YoY to 61.5%, demonstrating strength in the company's subscription customer base.

• New Strategic Partnerships

  • Launched the company's first large-scale white-label co-branded online pharmacy with Rural King in July 2026, serving 150+ stores across 17 U.S. states. This partnership leverages PetMeds' existing pharmacy infrastructure, licensed pharmacists, and e-commerce expertise to convert in-store Rural King customers into online PetMeds customers, opening a new low-cost customer acquisition channel and new revenue stream.
  • Management expects to expand this white-label offering to additional partner companies in the near future.

• Corporate Updates

  • The company received an unsolicited, non-binding, conditional proposal from Silver Cape Investments to acquire all outstanding shares of PetMeds for $3 per share in cash. The board has not yet made a determination on the proposal, and there is no guarantee a transaction will be completed.
  • A permanent CEO search is ongoing with support from a global executive search firm, and this remains a high priority for the board.

• Capital Allocation

  • Entered a definitive sale-leaseback agreement for the company's Delray Beach, Florida headquarters and distribution center for $37 million. The transaction is expected to close within 120 days, subject to customary closing conditions. PetMeds will lease back its operating space for a 10-year term with renewal options. The transaction unlocks real estate value, strengthens the balance sheet, and provides additional financial flexibility to invest in high-impact shareholder value initiatives.

• Balance Sheet

  • As of June 30, 2026, the company held $13.1 million in cash and cash equivalents with no outstanding debt.

Management did not issue specific numerical financial guidance for future periods, nor did it announce upward, downward, or maintenance revisions to prior guidance during the call. The company only provided qualitative forward-looking statements noting that its 12 months of operational, financial, and strategic improvements have created a stronger, more scalable foundation that positions the company to achieve its goals of returning to sustainable profitability and driving long-term shareholder value.

The call does not break out financial performance for multiple distinct product segments. Only aggregate company-level results are provided: Q1 2027 net sales totaled $41 million, a 19.9% year-over-year decline from $51.2 million in Q1 2026. Gross profit was $11.3 million (27.6% of net sales), compared to $14.4 million (28.1% of net sales) year-over-year. General and administrative expenses were $11.2 million, a 13.5% YoY decline from $12.9 million. Advertising expenses were $4.2 million, a 30.2% YoY decline from $6 million. Depreciation and amortization was $2.1 million, down from $2.3 million YoY. Net loss was $6.1 million ($0.28 per diluted share), narrowed significantly from a $34.2 million net loss ($1.65 per diluted share) in Q1 2026. Adjusted EBIT loss was $3.4 million, compared to a $2.7 million loss YoY. Recurring revenue (from auto-ship and membership programs) contributed 61.5% of total gross sales, up from 57.6% YoY.

• Forward-looking statements about future operational and financial results are inherently uncertain, and actual outcomes may differ materially from projected results, due to a range of unknown risks.
• The direct-to-consumer pet health market remains intensely competitive, which creates pressure on sales growth and profitability.
• Traditional advertising and customer acquisition channels continue to grow more expensive, which could pressure marketing costs and customer acquisition efficiency if the company's diversification strategy does not meet expectations.
• There is no assurance that the proposed acquisition by Silver Cape Investments will be completed, or that any transaction will result from the proposal.
• The pending sale-leaseback transaction is subject to customary closing conditions (including due diligence, lease negotiation) and may not close within the expected 120-day timeframe or at all.
• Additional risk factors affecting the company's operations are detailed in its most recent Form 10-K and other SEC filings.

There were no question-and-answer exchanges included in the provided transcript.